Company Overview
Sonoma Pharmaceuticals is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company's products, which are sold throughout the world, have improved outcomes for more than ten million patients globally by reducing infection, itch, pain, scarring and harmful inflammatory responses. Sonoma's headquarters are in Petaluma, California, with manufacturing operations in both the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands.

Sonoma Pharmaceuticals Announces Closing of $1.6 Million Public Offering of Common Stock
Nov 29 2019, 4:42 PM EST

Sonoma Pharmaceuticals Announces Pricing of Approximately $1.6 million Public Offering of Common Stock
Nov 26 2019, 10:10 AM EST

Sonoma Pharmaceuticals Announces Proposed Public Offering of Common Stock
Nov 25 2019, 7:54 PM EST

Management Team
Amy Trombly
Interim Chief Executive Officer
Bruce Thornton
Executive Vice President
John Dal Poggetto
Chief Financial Officer
Robert Northey Ph.D
Director of Research and Development

Sonoma Pharmaceuticals, Inc.
1129 North McDowell Blvd.
Petaluma, CA 94954

Disclaimer
Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements.

All trademarks and brand name are the property of their respective companies.